Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Unusually-High Trading Volume – Here’s Why

Posted by on Jul 28th, 2026

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) saw strong trading volume on Tuesday . 1,500 shares traded hands during mid-day trading, an increase of 384% from the previous session’s volume of 310 shares.The stock last traded at $48.2050 and had previously closed at $49.0282.

Wall Street Analysts Forecast Growth

BIOVF has been the topic of a number of research analyst reports. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. HC Wainwright began coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They issued a “buy” rating for the company. Zacks Research upgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Check Out Our Latest Stock Analysis on Swedish Orphan Biovitrum

Swedish Orphan Biovitrum Trading Down 1.7%

The stock’s 50 day moving average is $48.14 and its 200-day moving average is $42.78. The company has a market cap of $17.16 billion, a P/E ratio of 107.12 and a beta of 0.35. The company has a current ratio of 0.70, a quick ratio of 0.47 and a debt-to-equity ratio of 0.19.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. The business had revenue of $755.76 million during the quarter, compared to analyst estimates of $749.76 million. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 18.27%. Research analysts anticipate that Swedish Orphan Biovitrum will post 1.94 earnings per share for the current fiscal year.

Swedish Orphan Biovitrum Company Profile

(Get Free Report)

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.

Featured Articles

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.